News About: Pharm. Affairs
Potential domestic vaccines against multinational companies’ ones
Vaccine is one of the fields which have become energetic as a part of ‘prevention.’ As people started to give more importance towards ‘prevention’ than ‘treatment,’ development of vaccines have naturally been influenc...
When domestic companies will win patent suits over ‘Revlimid’?
Domestic pharmaceutical companies have filed patent suits to preoccupy the market of the multiple myeloma therapy whose substance patent will be expired next year, ‘Revlimid,’ but they continued failure.
Celgene’s ...
More generics on Tarceva over Iressa facing patent expiration
While blockbuster targeted drugs, Roche’s ‘Tarceva’ and AstraZeneca’s ‘Iressa’ will be expired in patent, there are more pharmaceutical companies which acquired approval on Tarceva generics than the one of Iressa even...
‘Waiting group’ vs ‘hardliners’ over Lyrica
The market of generics for the painkiller, ‘Lyrica,’ has been fueled. As about 30 products were newly approved only this year, the list of products waiting for Lyrica now consists of more than 100 products.
Unlike th...
Trend of combination therapies for acne, led by multinational companies
Acne is a major disease which patients visit dermatologists for a long term for.
Fortunately, there are various types of acne therapies in the market unlike the past. As long as patients find suitable drugs for thei...
Roche’s one more attempts on Alzheimer’s disease therapies
In the Alzheimer’s disease therapy market, Roche was known to recently start domestic clinical trials one after another. Since they are clinical trials after experiencing failures on the two drugs for clinical trials ...
‘Keytruda’ administration test method accepted as new medical technology
A diagnostic check method which is used to decide administration of ‘Keytruda(pembrolizumab),’ an immunotherapy which attracted interests over the health insurance benefit, will be accepted as a new medical technology...
“I expect the role of LAI Invega Trinza on schizophrenia”
In the market of schizophrenia, whose key of treatment is to prevent recurrence prevention, the domestic approval of ‘Invega Trinza,’ a long-acting injection(hereinafter referring to LAI), has attracted attention.
At...
Erbitux’s enjoyment over RSA effect, Viread’s explosive upturn
‘Erbitux,’ the Merck’s targeted therapy for metastatic colorectal cancer, has well enjoyed the effect of the risk-sharing system.
Moreover, ‘Viread,’ the Gilead’s hepatitis B treatment, has shown an incredible growt...
The pharmacy is the ‘out of stock’ GSK is ‘supply’... Where is the many Dermovate?
Is it ‘out-of-stock’? It actually was told it has been supplied, though. Where all the drug could go?
The mystery of GSK’s Dermovate Soln 25ml & 50ml has reoccurred.
While the pharmaceutical company said it has supp...
